Alta prevalencia de consumo de neurolépticos en las personas ancianas con demencia

Fort, Isabel; Formiga, Francesç; Robles, María José; Regalado, Pedro; Rodríguez, Daniel; Barranco, E.

doi:10.1016/j.medcli.2009.07.046

Cited by 14 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our 15.5% exposure rate for demented patients is consistent with previous published rates, which ranges from 15% to 50% of the demented populations studied (Ellul et al, 2007;Fort et al, 2010;Child et al, 2012;Rattinger et al, 2013). Compared with the general age-matched population, dementia diagnosis is associated with approximately a three times higher risk of being prescribed at least one psychotropic drug.…”

Section: Discussionsupporting

confidence: 89%

Exposure to psychotropics in the French older population living with dementia: a nationwide population‐based study

Breining

Bonnet-Zamponi

Zerah

et al. 2016

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Exposure to psychotropics in the French older population living with dementia: a nationwide population‐based study

Breining

Bonnet-Zamponi

Zerah

et al. 2016

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…Nevertheless, 40% of the patients were prescribed an anxiolytic, and more than half of the cases consumed antidepressants and analgesics. These frequencies are in agreement with the observations by other authors in Spain and the USA [16,37]. However, Ellul et al [19] described frequencies of antidepressant consumption under 30% in the UK.…”

Section: Discussionsupporting

confidence: 92%

“…Regarding antipsychotics, serious side effects and increased mortality risk have been repeatedly documented [11,39,40], but they are broadly used in patients with dementia [15,37]. Yet, according to our results, early diagnosed patients (<12 months) were less frequently prescribed an antipsychotic (18.4%) compared to those diagnosed later (30.8% in ≥36 months).…”

Section: Discussionmentioning

confidence: 49%

Central Nervous System Drug Consumption Depending on the Time between Symptom Onset and the Diagnosis of Alzheimer’s Disease: An Analysis by the Registry of Dementias of Girona

Calvó-Perxas

López-Pousa²,

Vilalta-Franch³

et al. 2012

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Aims: To describe central nervous system (CNS) drug consumption patterns depending on the time to diagnosis of Alzheimer’s disease (AD), and to check whether the cases diagnosed later are associated with greater severity and consuming more CNS drugs. Methods: Cross-sectional study using 952 cases of the Registry of Dementias of Girona. A binary logistic regression was used to detect variables associated with the use of CNS drugs depending on the time to diagnosis. Results: CNS drugs were consumed by 95.8% of the AD patients. Only antipsychotics presented a statistically significant increase in the frequency of prescription to patients with longer time elapsed from symptom onset to AD diagnosis. Conclusion: Longer time elapsed from the onset of symptoms to the diagnosis resulted in increased probability of antipsychotic consumption.

show abstract

“…The lower MMSE score at the time of diagnosis may be related to the greater treatment with antipsychotics; however, high rates of antipsychotic consumption have been previously reported both in the ReDeGi [39, 50] and in Catalonia [51], which warrants further study regarding mortality risks, medication side-effects, and drug-drug interactions. On the other hand, cardiovascular medications were also more common in the ReDeGi than in SveDem, which seems to be in disagreement with the North-South gradient of cardiovascular risk, but may be related with the differences seen on AD/VaD rates.…”

Section: Discussionmentioning

confidence: 99%

Diagnosis of Dementia in the Specialist Setting: A Comparison Between the Swedish Dementia Registry (SveDem) and the Registry of Dementias of Girona (ReDeGi)

Garré-Olmo

García-Ptacek

Calvó-Perxas

et al. 2016

JAD

View full text Add to dashboard Cite

The aim of this study was to compare the frequency of dementia diagnoses from two dementia registries in Europe. Patients registered between 2007 and 2013 in the Swedish Dementia Registry (SveDem; Sweden) and in the Registry of Dementias of Girona (ReDeGi; North-East of Spain) were selected. We compared sociodemographic data, Mini-Mental State Examination (MMSE) scores, dementia subtype, and medication consumption of 22,384 cases from SveDem and 5,032 cases from ReDeGi. The average age (78.1 years SveDem versus 79.7 years ReDeGi) and the gender (female 58.2% SveDem versus 61.5% ReDeGi) did not greatly differ. MMSE score at diagnosis was higher for SveDem cases (22.1 versus 17.8). Alzheimer’s disease (AD) accounted for the main dementia subtype (36.6% SveDem versus 55.6% ReDeGi). The proportion of vascular dementia (VaD) and mixed dementia was higher in SveDem (18.8% versus 6.4% and 24.9 versus 13.4%), with an odds ratio (OR) and 95% confidence interval (CI) for SveDem relative to the ReDeGi of 3.41 (3.03–3.84) for VaD, and 2.15 (1.97–2.35) for mixed dementia. This was at the expense of a lower frequency of AD in SveDem (OR 0.41; 95% CI 0.39–0.44). Other dementia diagnoses such as frontotemporal dementia or dementia with Lewy bodies did not significantly differ between registries (2.3% versus 2.9%; 1.9 versus 3.1%). Large differences in medication consumption at the time of dementia diagnosis were detected (4.7 treatments SveDem versus 6.8 ReDeGi). Northern and southern European dementia cohorts differ in demographic characteristics, MMSE score at diagnosis, and drug treatment profile.

show abstract

Alta prevalencia de consumo de neurolépticos en las personas ancianas con demencia

Cited by 14 publications

References 26 publications

Exposure to psychotropics in the French older population living with dementia: a nationwide population‐based study

Exposure to psychotropics in the French older population living with dementia: a nationwide population‐based study

Central Nervous System Drug Consumption Depending on the Time between Symptom Onset and the Diagnosis of Alzheimer’s Disease: An Analysis by the Registry of Dementias of Girona

Diagnosis of Dementia in the Specialist Setting: A Comparison Between the Swedish Dementia Registry (SveDem) and the Registry of Dementias of Girona (ReDeGi)

Contact Info

Product

Resources

About